Fisher & Paykel Healthcare (ASX:FPH) LT-Debt-to-Total-Asset: 0.04 (As of Mar. 2026)

What is Fisher & Paykel Healthcare LT-Debt-to-Total-Asset?

Fisher & Paykel Healthcare ASX:FPH +1.33% 90 LT-Debt-to-Total-Asset is 0.04 as of Mar. 2026. GuruFocus rates ASX:FPH with a GF Score™ of 90/100 and a GF Value™ of A$36.41 (Modestly Undervalued). The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Fisher & Paykel Healthcare's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.04.

Fisher & Paykel Healthcare's long-term debt to total assets ratio increased from Mar. 2025 (0.03) to Mar. 2026 (0.04). It may suggest that Fisher & Paykel Healthcare is progressively becoming more dependent on debt to grow their business.

Fisher & Paykel Healthcare (ASX:FPH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Fisher & Paykel Healthcare LT-Debt-to-Total-Asset Related Terms

Fisher & Paykel Healthcare LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Fisher & Paykel Healthcare's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fisher & Paykel Healthcare LT-Debt-to-Total-Asset Chart

Fisher & Paykel Healthcare Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.06

0.04

0.03

0.04

Fisher & Paykel Healthcare Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.03	0.03	0.02	0.04

90GF Score

Fisher & Paykel Healthcare Corp Ltd ASX:FPH

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Fisher & Paykel Healthcare LT-Debt-to-Total-Asset Calculation

Fisher & Paykel Healthcare's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (A: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2026 )	/	Total Assets (A: Mar. 2026 )
	=	94.417	/	2378
	=	0.04

Fisher & Paykel Healthcare's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	94.417	/	2378
	=	0.04

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.04 mean?

Fisher & Paykel Healthcare (ASX:FPH) has a LT-Debt-to-Total-Asset of 0.04 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Fisher & Paykel Healthcare and its competitors.

Is Fisher & Paykel Healthcare's LT-Debt-to-Total-Asset too high?

Fisher & Paykel Healthcare's current LT-Debt-to-Total-Asset is 0.04. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Fisher & Paykel Healthcare's LT-Debt-to-Total-Asset compare to ISRG and BDX?

Fisher & Paykel Healthcare's LT-Debt-to-Total-Asset of 0.04 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Fisher & Paykel Healthcare and its competitors. Fisher & Paykel Healthcare's current LT-Debt-to-Total-Asset is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Fisher & Paykel Healthcare stock overvalued right now?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.41, compared to a current price of A$31.99 — trading 12.1% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.04. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current LT-Debt-to-Total-Asset is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?

Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued. The current stock price of A$31.99 is trading 12.1% below its estimated GF Value™ of A$36.41. GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.

Key valuation signals for ASX:FPH:

LT-Debt-to-Total-Asset: 0.04
GF Value™: A$36.41 vs. price of A$31.99 (12.1% below fair value)
GF Score™: 90/100 with 2 warning signs

No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fisher & Paykel Healthcare Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies NZSE:TRU ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543 XPAR:DIM COO SOLV OCSE:COLO B ALGN BAX NSE:LENSKART RGEN ATR

Other Exchanges FSPKF:USA FPH:New Zealand

Address 15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013

Website https://www.fphcare.com

Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.

90GF Score

Get the complete analysis for ASX:FPH

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$31.99

Price

A$36.41

GF Value

View ASX:FPH Analysis

See LT-Debt-to-Total-Asset data for all stocks →